

Journal section: Periodontology
Publication Types: Review

doi:10.4317/jced.56324
<https://doi.org/10.4317/jced.56324>

Effects of timing of adjunctive systemic antibiotics on the clinical outcome of periodontal therapy: A systematic review

Lamiaa Abdallaoui-Maan ¹, Amal Bouziane ^{1,2}

¹ Department of periodontology, Faculty of Dental Medicine, Mohammed V University in Rabat, Morocco

² Laboratory of Biostatistics, Clinical Research and Epidemiology, Mohammed V University in Rabat, Morocco

Correspondence:
BP 6212 Madinat Al Irfane
Rabat, Morocco
lamiaabdallaoui@gmail.com

Received: 20/09/2019
Accepted: 25/11/2019

Abdallaoui-Maan L, Bouziane A. Effects of timing of adjunctive systemic antibiotics on the clinical outcome of periodontal therapy: A systematic review. J Clin Exp Dent. 2020;12(3):e300-9.

Article Number: 56324 <http://www.medicinaoral.com/odo/indice.htm>
© Medicina Oral S. L. C.I.F. B 96689336 - eISSN: 1989-5488
eMail: jced@jced.es
Indexed in:
Pubmed
Pubmed Central® (PMC)
Scopus
DOI® System

Abstract

Background: Many systematic reviews and meta-analysis have indicated beneficial effects of adjunctive systemic antibiotics in periodontal therapy in specific situations. However, some essential issues such as the ideal time of their administration during periodontal therapy remain unanswered. This systematic review aimed to determine at which phase of periodontal treatment would adjunctive systemic antibiotics lead to the best clinical outcomes, during the active phase or in the reevaluation phase.

Material and Methods: Searches in the databases Medline, Scopus and Cochrane Library were conducted. The randomized clinical trials and retrospective cohort studies comparing the clinical benefits of adjunctive systemic antibiotic administration in the active phase of periodontal treatment versus their administration in the reevaluation phase were included. The primary outcomes assessed were differences in clinical changes in periodontal pocket depth and clinical attachment loss at all post-treatment phases.

Results: Of the 6209 records identified, two randomized clinical trials and two retrospective cohort studies were eligible according to inclusion criteria. Two studies suggested there were greater clinical benefits when systemic antibiotics were prescribed during the active phase of periodontal therapy than in the reevaluation phase while two other studies showed no significant difference in clinical outcomes at 6 months between these two different timing of administration.

Conclusions: The evidence available and evaluated in this systematic review is of heterogeneous quality and limited by the restricted number of studies and their dissimilarities in their study design and outcome reporting. Despite insufficient evidence to determine the ideal time to the adjunctive systemic antibiotic administration in the periodontal therapy, it seems that prescription of systemic antibiotic at the active phase of periodontal therapy leads to better clinical outcomes.

Key words: Active phase; periodontal therapy, periodontitis, reevaluation, systemic antibiotics, timing.

Introduction

The use of systemic antimicrobials as adjunct to mechanical therapy has been indicated to potentiate the effects of non-surgical mechanical therapy in the cases of aggressive periodontitis, severe and progressive periodontitis and in periodontitis associated with specific microbiological profiles (1,2). Many reports, systematic reviews and meta-analysis have indicated beneficial effects of systemic antibiotics for patients with periodontal disease in these clinical situations (1-5) with more pronounced effects in aggressive periodontitis than in chronic periodontitis and in initially deep sites compared with moderately deep sites (6). A wide range of systemic antibiotics has been tested in clinical studies demonstrating superiority of the combination of amoxicillin and metronidazole over any other antibiotic agent in the treatment of different forms of periodontitis. However, there is currently insufficient high quality evidence to recommend a specific agent, dose or duration (7). The optimal time of antimicrobial drug administration is another subject of discussion, as it remains controversial whether adjunctive systemic antibiotics should preferably be administered during the initial non-surgical phase, or during the subsequent re-treatment at reevaluation.

At present, there is very little data to guide the selection of the most appropriate timing of antibiotic administration (8). Basing on some biological concepts, some studies recommend the use of systemic adjunctive antibiotic agents at the initial phase of treatment (9-11), as it was recommended in the consensus report of the sixth European Workshop on Periodontology (12). However, in light of the enhanced antibiotic resistance development, other reports support that it would be more judicious to reevaluate each patient's response to non-surgical periodontal therapy before deciding to prescribe or not adjunctive systemic antibiotic therapy (6).

Therefore, this systematic review aims to determine which is the optimal time of systemic antibiotic administration as an adjunct to periodontal therapy, during the active non-surgical phase or the reevaluation phase.

Material and Methods

-Protocol and registration

This Systematic review was conducted according to the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) statement (13) and registered at the International Prospective Register of Systematic Reviews (PROSPERO) under the number CRD42019123386.

-Focused Question

The review was conducted to assess whether timing of systemic adjunctive antibiotics influenced the outcomes of periodontal therapy. Specifically, the purpose of this review is to answer the following question: "Would adjunctive systemic antibiotic administration in the active

phase of periodontal therapy provides greater clinical benefits than in the reevaluation phase?"

-Eligibility Criteria

Studies were assessed for eligibility based on the following criteria:

1. Study type: randomized control trials (RCT), or controlled clinical trials (CCT), and retrospective cohort studies (RCS) were eligible for inclusion. Case-control studies were excluded. A minimum follow-up period of two months was required, but no restrictions were placed on the type of setting, language or year of publication.
2. Participants: patients with clinically diagnosed periodontitis were eligible for inclusion. Patients who didn't require antibiotic prescription were excluded.
3. Intervention: clinical studies comparing at least two groups, one test (systemic antibiotic administered at the reevaluation phase of periodontal therapy) and one control (systemic antibiotic administered at the active phase of periodontal therapy) were eligible for inclusion. The studies administering systemic antibiotic without associated mechanical debridement or using local antibiotics or antibiotics in sub-antimicrobial doses were excluded.
4. Outcome variables were differences in clinical changes in Periodontal Pocket Depth (PPD) and Clinical Attachment Loss (CAL) at all post-treatment points between the test and control groups.

-Information Sources

An electronic search of Medline, Scopus and the Cochrane Library databases was performed on the 26th of October 2018 for eligible clinical studies. The reference lists of all included studies and relevant reviews were manually cross-referenced to complete data collection.

-Search Strategy

The following search strategy was used for the Medline database and adapted adequately for the Scopus and Cochrane Library searches:

≠1 ("periodontal diseases" OR periodontitis OR "chronic periodontitis" OR "aggressive periodontitis" OR "periodontal infection") AND ("anti-infective agents" OR "antibacterial agents" OR "antimicrobial" OR antibiotics) AND (tim* OR delay OR phase) NOT photodynamic.

-Study Selection

The search results were downloaded into a Zotero library. After removing duplicates, the library was saved and two reviewers (LA and AB) screened titles and abstracts for eligibility. Full text articles for all studies that appeared to meet the inclusion criteria or could not be excluded for sure were obtained. Each article was assessed independently against the eligibility criteria by two reviewers (LA and AB) and reasons for exclusion were reported. Disagreements between reviewers were argued and resolved by discussion.

-Data Collection & Items

Two independent reviewers (LA and AB) collected Data

from each included article. The following items were recorded within each included study: sample characteristics, length of the study, diagnosis, treatment performed in test groups and controls (including the protocol of scaling and root planning (SRP) (full-mouth or by quadrant), the antibiotic molecule, its dose, timing, frequency and duration and follow-up. The comparison of primary and secondary outcomes between test and control groups with statistical significance were also recorded.

-Assessment of Risk of bias

Two independent review authors (LA and AB) assessed the methodological quality of each study. Discrepancies were resolved by discussion to reach a consensus.

Assessment of Risk of bias in clinical trials included was performed in accordance with the Cochrane Handbook for Systematic Reviews of Interventions (14). Studies were assessed on seven criteria constituting potential sources of bias: Sequence generation, Allocation concealment, Blinding of participants and personnel, Blinding of outcome assessors, Incomplete outcome data, Selective outcome reporting, Others bias. Each criterion was judged at low risk of bias (yes), high risk of bias (no) or unclearly determined (unclear). The risk of bias of each study was then assessed as: "Low risk of bias": if "yes" is found in all domains; "High Risk of Bias": if "no" is met in any of the domains and "Unclear Risk of Bias": if "unclear" is recorded in any of the domains.

Assessment of Risk of bias in retrospective cohort studies included was performed in accordance with the Newcastle-Ottawa quality assessment scale for cohort studies (15). This scale is a 'star' rating system comprising three domains: selection of study groups, comparability of groups, and outcome of interest assessment. Each criterion fulfilled is awarded by a one star.

A study can be given a maximum of one star for each numbered criteria within the Selection and Outcome categories. A maximum of two stars can be allocated for Comparability category. A maximum of nine stars can be given for each study. The following thresholds were used for converting the Newcastle-Ottawa scales to Agency for Healthcare Research and Quality (AHRQ) standards (good, fair and poor) (15):

- If 3 or 4 stars were allocated in selection domain AND one or 2 stars in comparability domain AND 2 or 3 stars in outcome/exposure domain, the RCS is considered of "good quality".
- If 2 stars were allocated in selection domain AND one or 2 stars in comparability domain AND 2 or 3 stars in outcome/exposure domain, the RCS is considered of "fair quality".
- If no or one star was allocated in selection domain OR no star in comparability domain or one star in outcome/exposure domain, the RCS is considered of "poor quality".

Results

-Study selection

The search strategy identified 2609 records from Medline, Scopus And Cochrane Library. After reading the titles and abstracts, 2598 studies were excluded, and 11 were selected. No article was identified in the manual search. After reading the full text of the 11 selected studies, 7 were excluded (10,16-21) and 4 of them met the inclusion criteria (22-25) (Fig. 1). A flowchart for the study selection process is presented in Figure 1.

-Study characteristics and heterogeneity

Of the 4 included studies, 2 randomized controlled trials (22,23) and 2 retrospective cohort studies (24,25) reported on 187 patients, which included 94 test subjects and 93 controls.

Two studies selected patients with generalized aggressive periodontitis (22,24), one study with localized aggressive periodontitis(25), and one study included *Aggregatibacter actinomycetemcomitans*-associated moderate to advanced periodontitis including both chronic and aggressive periodontitis and participants aged up to 70 years (23). Smokers were not excluded from studies except for one study who was also restricted to an African-American population (25).

Follow up times varied from 6 months to 15 months. However, not all studies reported 3 months results after initial therapy (22).

The mode of non-surgical treatment varied between full mouth instrumentation (22,23,25), or quadrant instrumentation in four visits within two weeks (24), and all participants of studies used 0.2% chlorhexidine mouthwashes after treatment during 10 to 15 days.

The dose and duration of antibiotic regimens used in the 4 included studies also varied, as outlined in table 1, 1 cont. Amoxicillin was administered in 375 and 500mg doses, while metronidazole was administered in 250 and 500mg doses. All doses were given three times daily, and the duration of antibiotic therapy ranged between 7 and 10 days.

A re-treatment was performed by all the studies in the re-evaluation at 3 months after the initial phase (non-surgical treatment) except for one study in which the re-treatment was performed at 6 months after initial therapy (22).

Different approaches to treat the persistent residual pockets were tested at the re-evaluation phase consisting of a non-surgical re-treatment in all studies except for one study which performed both non-surgical and surgical re-treatment based on the values of the periodontal pockets depths, bleeding on probing and furcation involvement (23).

The primary outcomes studied were also heterogeneous between the included studies (PPD reduction at sites with initial PPD \geq 7mm (22), number of sites per patient with PPD $>$ 4mm and that bleed after probing (BOP+)




Fig. 1: Prisma flowchart of study selection process.

(23), reductions of full mouth Probing Depth (PD) and Relative Attachment Levels (RAL)(24), reductions in mean Clinical Attachment Level (CAL) (25).

A summary of the characteristics of the included studies is reported in Table 1, 1 cont..

-Results of Individual Studies:

In Griffith's study (22), both treatments i.e. antibiotics initially and antibiotics at the re-treatment resulted in improvements of the mean PPD and LCAL(lifetime clinical attachment level) at both 6 and 8 months. The difference in mean PPD in deep pockets (≥ 7 mm) was statistically and clinically significant between the 2 groups, with a difference of 0.9mm ($P<0.001$) at 2 months, 1.4mm ($P<0.001$) at 6 months and 0.9mm ($P<0.003$) at 8 months in favor of the group who had antibiotic initially. Similar patterns were observed for LCAL with statistically significant differences, but with a lower greatness of difference.

According to the study of Mombelli (23), the administration of the amoxicillin plus metronidazole in the first or second phase resulted in similar long-term outcome. At 3 and 6 months after initial therapy, the mean number of sites with pocket depths PD >4 mm and BOP per patient was significantly lower than at baseline in both groups, with no significant difference between the two

groups ($P=0.18$, $P=0.61$ respectively). However, administering adjunctive antibiotics in the first phase result in fewer patient requiring further therapy, a shorter treatment time and a lower mean number of surgical interventions. In the retrospective study of Kaner (24), giving systemic antibiotics as an adjunct to SRP resulted in significant clinical improvements over 6 months in both group A (immediate antibiotics group) and group B (late antibiotics group). However, except for BOP, the changes in all clinical parameters over time were significantly different between the two groups. At 3 months after the initial therapy, the immediate administration of antibiotics resulted in significantly greater reductions in PD and RAL (for full- mouth means and for initially deep sites) and in the proportion of sites with PD >6 mm compared to SRP alone in the late antibiotics group. After 6 months, both groups showed comparable changes in full-mouth PD and RAL, BOP and pus, and the proportions of deep sites (PD >6 mm). However, the immediate antibiotic group obtained statistically significantly higher reductions in the mean PD (-4.09 mm) and RAL (-2.50 mm) in deep sites (with PD >6 mm) in comparison with the late antibiotic group (-2.80 mm and -1.41 mm, respectively) ($P<0.05$). The study of Beliveau (25) showed that administration of an antibiotic protocol immediately following mecha-

Table 1: Summary of the characteristics and findings of the included studies.

Authors, year	Study type	Study length	Sample	Disease	Treatment					
Griffiths <i>et al.</i> 2011 (23)	RCT	8 months	N=41 16-35Y F : 28 M : 13 S : 9	GAgP	FIRST PHASE (initial phase)			SECOND PHASE (retreatment)		
					Group A (n =20) FMRSD + ATB (AMOX 500 mg + MTZ 500 mg t.i.d / 7days) + CHX/2 weeks Group B (n= 21) FMRSD + placebo+ CHX/2weeks			6 months after first phase Follow-up: 2 months Group A (n=19) FMRSD + CHX/2 weeks without placebo Group B (n= 19) FMRSD + ATB (AMOX 500 mg + MTZ 500 mg t.i.d /7days) + CHX/2 weeks		
					Clinical Outcome					
					M2T1		M6T1		M8T2	
					Differences in mean PPD reduction in pockets ≥7mm in favor of group A (Estimate 95%CI)					
					0.9 (0.4,1.5) <i>P</i> =0.001		1.4 (0.8,2.0) <i>P</i> <0.001		0.9 (0.3,1.5) <i>P</i> =0.003	
					% of sites with ≥2mm of PPD reduction M(IQ)					
					GA : 29(24,44) GB : 21(11,33) <i>P</i> =0.029		GA : 30 (21,47) GB : 21 (9-33) <i>P</i> = 0.021		GA : 31 (24,46) GB : 27 (19,39) <i>P</i> =0.179	
Differences in mean gain in LCAL in pockets ≥7mm (Estimate in favor of group A (Estimates 95%CI)										
0.6 (0.2,0.9) <i>P</i> =0.002		1.0 (0.7,1.3) <i>P</i> <0.001		0.7(0.2,1.6) <i>P</i> =0.007						
Authors, year	Study type	Study length	Sample	Disease	Treatment					
Mombelli, <i>et al.</i> 2015 (24)	RCT Cross-over clinical design	15 months	N=80 25-70 y F : 39 M : 41 S : 33	Moderate To advanced periodontitis Aa+ (65 CP, 15 AP)	PHASE T1 (non-surgical periodontal therapy)			PHASE T2 (surgical periodontal therapy)		
					Group A (n=40) SRP ^(a) + ATB(AMOX 375 mg+MTZ 500 mg tid/7 days) + CHX/10days Group B (n=40) SRP ^(a) + Placebo+ CHX/10days ^(a) Full mouth within 48h			3 months after phase T1 Follow-up: 12 months Group A (n= 38) <ul style="list-style-type: none"> Open flap debridement of all teeth with residual PD ≥6mm and all furcation involved teeth with residual pockets ≥5mm SRP to sites with residual PD between 4 and 5 mm + Placebo+ CHX/10days Group B (n= 37) <ul style="list-style-type: none"> Group A protocol + ATB(AMOX 375 mg + MTZ 500mg t.i.d/7days) +CHX/ 10days 		
					Clinical Outcome					
					BASELINE		M3T1		M6T2	
					Number of sites with PD >4mm and BOP per patient (M±SD)					
GA : 34.5±29.0 GB : 28.7±19.7 <i>P</i> = 0.29		GA : 5.7±9.0 GB : 8.7±10.3 <i>P</i> = 0.18		GA : 2.8±5.2 GB : 2.2±5.0 <i>P</i> = 0.61						
Number of participants with persistence of sites with PD >4 mm and BOP (%)										
		GA : 25 (64.1%) GB : 34 (89.5%) <i>P</i> =0.01		GA : 11 (29.7%) GB : 15 (42.9%) <i>P</i> = 0.33						

Table 1 cont.: Summary of the characteristics and findings of the included studies.

Authors, Year	Study design	Length study	Sample	Disease	Treatment		
Kaner <i>et al.</i> 2007 (25)	RCS	6 months	N=34 18-40y F:17 M:17 CS:11	Advanced GAgP	<p>Group A (n=17)</p> <p>SRP^(b) + <u>immediate ATB</u> (AMOX 500+MTZ250 every 8h/10 days)</p> <p>Group B (n=17)</p> <p>SRP^(b) (subgingival instrumentation at BOP positive sites with PD≥4mm and at all sites exhibiting PD≥5mm) +<u>Late ATB</u> (AMOX 500+MTZ250 every 8 h /10 days) after 3months</p> <p>^(b) SRP by quadrant in 4 visits within 2 weeks</p>		
					Clinical Outcome		
					0-3 months	3-6months	0-6 months
					Reduction in proportion of sites with PD >6mm (%)		
					GA: -37 GB: -24 P= 0.017	GA: 0 GB: -7 P= 0.007	GA: -37 GB: -30 P= 0.291
					Mean changes PD (sites with deep pockets PD>6mm) (95%CI)		
					GA: -3.83 (-4.16, -3.5) GB: -2.03 (-2.38-1.69) P<0.001	GA: -0.26 (-0.54,0.22) GB: -0.77 (-1.06, -0.48) P= 0.011	GA: -4.09 (-4.42, -3.76) GB: -2.80 (-3.14, -2.46) P<0.001
Mean changes in RAL (sites with deep pockets PD>6mm)							
GA: -2.41 (-2.77, -2.05) GB: -0.79 (-1.17, -0.42) P<0.001	GA: -0.09 (-0.33,0.16) GB: -0.62 (-0.87, -0.36) P= 0.004	GA: -2.50 (-2.91,2.08) GB: -1.41 (-1.84, -0.98) P<0.001					
Authors, Year	Study design	Length study	Sample	Disease	Treatment		
Beliveau <i>et al.</i> 2012 (26)	RCS	6 months	N=32 African- Américain 7-21 Y F: 23 M: 9	LAgP	<p>ImA group (n=17)</p> <p>SRP^(c) + ATB (AMOX 500+ MTZ 250 t.i.d/7 days) immediately after the initial mechanical therapy</p> <p>DelA group (n=15)</p> <p>SRP + ATB (AMOX 500+ MTZ 250 t.i.d/7 days) at 3 months post-initial mechanical therapy</p> <p>^(c) SRP by full mouth debridement</p>		
					Clinical Outcome		
					Baseline	3 months	6 months
					Number of residual sites with PD>4 mm for diseased sites (PD>4 mm+BOP+CAL≥2mm) (M ±SD)		
					ImA: 19.5±15.1 DelA: 19.7±11.7	ImA: 11.1±11.7 ^(d) DelA: 16.8±13.1 ^(e)	ImA: 9.4±11.1 ^(d) DelA: 7.8±6.6 ^(d)
					Number of residual sites with CAL >2 mm for diseased sites (PD>4 mm+BOP+ CAL≥2mm)		
ImA:15.9±13.6 DelA: 14.5±8.9	Im A:6.5±7.4 ^(d) Del A: 12.0±8.1	ImA: 6.2±9.2 ^(d) DelA: 4.5±4.8 ^(d)					

RCT : randomized clinical trial ; RCS: retrospective cohort study; N : number ; F : female ; M : male ; S: smoker; CS: current smoker; Y: years; GAgP : generalized aggressive periodontitis, LAgP : localized aggressive periodontitis ; SCP : severe chronic periodontitis, CP : chronic periodontitis; AP : aggressive periodontitis; Aa + : detection of Aggregatibacter actinomycetemcomitans in a pooled sample from the deepest pocket of each quadrant; SRP: scaling and root planning; FMRSD: full-mouth root surface debridement; ATB: antibiotic; AMOX: amoxicillin; MTZ: metronidazole; t.i.d: three times per day; CHX: 0.2% chlorhexidine; M3T1: Three months after SRP at T1 (initial phase); M6T2: Six months after T2(second phase treatment); ImA: immediate antibiotic; DelA: delayed antibiotic; PD: probing depth; PPD: periodontal pocket depth; CAL: clinical attachment level; RAL: relative attachment level; BOP: bleeding on probing; LCAL: life –time cumulative attachment loss; M(IQ): median and interquartile range; M±SD: Mean ± standard deviation; CI: Confidence-Interval; P: P-value; ^(d) P<0.05 from baseline by ANOVA with tuckey’s multiple comparisons; ^(e) P<0.05 between groups by unpaired T-test and Mann-Whitney test.

nical therapy resulted in significant reductions in mean CAL at both 3 and 6 months post-initial therapy while a significant reduction was observed only at 6 months in the delayed antibiotic (DeLA) group.

In addition, the percentage of sites with a PD >4mm was reduced in both immediate antibiotic (ImA) and DeLA groups six months post-therapy, although a statistically significant reduction in PD three months following treatment was observed only in the ImA group ($P<0.05$).

A decrease in the percentage of sites with CAL>2mm at both 3 and 6 months was also observed in the ImA group, while this decrease was observed only at 6 months in the DeLA group. Therefore, the early administration of antibiotics seems to result in a more rapid amelioration and maintenance of the major clinical parameters.

A summary of the results of the included studies is reported in Table 1.

-Risk of Bias Within Individual Studies:

The quality of each included clinical trial was assessed using the revised risk of bias assessment tool from the Cochrane Collaboration’s handbook version 5.1.0 (14). Based on the seven criteria analyzed, the Griffith’s study was estimated of “high risk of bias” and the Mombelli’s study “unclear risk of bias”, as it is depicted in Table 2.

Even if classified at low risk of bias in six of the seven criteria analyzed, the Griffith’s study was estimated at high risk of bias because of the absence of blinding of the participants and personnel to the treatment received. The Mombelli’s study was classified as having unclear risk of bias based on the uncertainty around three sources of bias. The quality of each retrospective cohort study included was assessed in accordance with the Newcastle-Ottawa quality assessment scale for cohort studies criteria and depicted in Table 3. The 2 RCS included scored indi-

Table 2: Assessment of risk of bias in randomized clinical trials (RCT) included in accordance with the Cochrane Handbook for Systematic Reviews of Interventions (14).

	Sequence generation	Allocation concealment	Blinding of participants and personnel	Blinding of outcome assessors	Incomplete outcome data	Selective outcome reporting	Others bias	Assessment
Griffiths et al. 2011 (23)	Yes	Yes	No ^(a)	Yes	Yes	Yes	Yes	High Risk of Bias
Mombelli et al. 2015 (24)	Yes	Unclear ^(b)	Yes	Yes	Yes	Unclear ^(c)	Unclear ^(d)	Unclear Risk of Bias

^(a) subjects were no longer blinded to the treatment received ; ^(b) Insufficient information to permit judgment; ^(c) It’s unclear if the 40 patients in each group were included in intention-to-treat-analysis; ^(d) The repartition of aggressive and chronic periodontitis cases is unclear within group A and B.

“yes”: Low risk of bias

“No”: High risk of bias

“Unclear”: Unclear risk of bias

Table 3: Assessment of risk of bias in retrospective cohort studies (RCS) included in accordance with the Newcastle-Ottawa quality assessment scale for cohort studies (15).

1. Selection	Kaner et al. 2007 (25)	Beliveau et al. 2012 (26)
1) Representativeness of the exposed cohort	–	–
2) Selection of the non-exposed cohort	–	–
3) Ascertainment of exposure	–	–
4) Demonstration that outcome of interest was not present at start of study	–	–
2. Comparability		
1)Comparability of cohorts based on the design or analysis	–	–
3. Outcome		
1) Assessment of outcome		
2) Was follow-up long enough for outcomes to occur	–	–
3) Adequacy of follow up of cohorts	–	–
Assessment	Good quality	Good quality

vidually 8 stars (4, 2 and 2 stars in respectively “selection”, “comparability” and “outcome” domains) and were rated good quality.

Discussion

The results of this systematic review demonstrated that up until today, only 4 studies including 2 RCS (24,25) and 2 RCT (22,23) in the literature compared the clinical effects of systemic antibiotics administered at different phases of mechanical therapy.

Among them, 2 studies including 1 RCT (22) of high risk of bias and 1 RCS (24) of good quality suggested there were greater clinical benefits when metronidazole and amoxicillin association was administered during the active phase of periodontal therapy than in the non-surgical re-treatment phase. Individuals treated with antibiotics together with SRP in the initial phase of treatment, showed greater reduction in PD and greater gain in CAL in deep pockets at all the time points than individuals treated later with antibiotics 3 or 6 months after SRP.

The 2 others studies including 1 RCT (23) of unclear risk of bias and 1 RCS (25) of good quality, included in this systematic review showed that giving antibiotics in the first or second phase have had no influence on the long term outcome. Six or 12 months after therapy, the mean number of sites with PD >4 mm and BOP per patient was significantly lower than at baseline in both groups, with no significant difference between the two groups. However, fewer patients treated with adjunctive antibiotics in the first phase needed further therapy (23,25), the treatment time in the second phase was shorter, and the mean number of surgical interventions was lower (23).

Furthermore, the differential microbiologic outcomes of this latest RCT was reported more recently and showed that giving the antibiotics during the first or second phase yielded similar microbiologic outcomes after 1 year although antibiotics in the first phase reduced bacterial counts quicker at 3 months (16). These findings were therefore in accordance with the clinical outcomes of this RCT (23).

It's important to point out therefore that in all these 4 studies (22-25), the immediate antibiotic usage at initial therapy provided beneficial clinical responses earlier in the treatment compared to the its later usage at reevaluation phase, thereby reducing the need for further therapy, which is both surgical and non-surgical in the RCT of Mombelli (23).

It is also worth considering that these studies present some limitations. First, the Griffith's study (22) was not initially designed to compare the effectiveness of the antibiotic given in different phases of treatment. It was a follow-up study of a randomized controlled trial which was performed in a previous study (26) in order to assess the adjunctive clinical effect of the administration of systemic amoxicillin and metronidazole in the non-sur-

gical treatment of generalized aggressive periodontitis (GAP).

Second, in this study, no placebo has been used in the second phase and the longitudinal evaluation time was short. The different follow-up times between immediate antibiotic group and delayed antibiotic group (6 months from initial antibiotic versus 2 months respectively) would constitute an additional limitation.

Furthermore, the heterogeneity between studies regarding the study design, the populations studied, the type of disease and severity, the modalities of non-surgical therapy (full mouth debridement or quadrant debridement), dosage and duration of antibiotherapy, the approaches of re-treatment (non-surgical exclusively or both non-surgical and surgical treatment) and the primary and secondary outcomes, makes terminating conclusions about the best time to prescribe adjunctive antibiotics in periodontal therapy difficult even if it emerges through these studies an early benefit for antibiotic administration in the active phase of treatment.

The conclusion of this review is somewhat consistent with another previous systematic review that compared the clinical effectiveness of systemic antibiotics administered in the active stage of periodontal treatment or after the healing phase (8). Only one study (22) was included in this review which did not allow authors to draw any clear conclusion. The present systematic review has an added value from methodological point of view (PRISMA recommendations, information sources, assessment of risk of bias,...), leading to more included studies, recent and available evidence to address the research question.

One double-blinded, three armed, placebo-controlled and bi-centric RCT was also designed to address the question of which is the best time for the administration of antibiotics in patients with severe periodontitis but it's still an ongoing trial and its findings have not been published yet (17).

Some biologic concepts support the use of antibiotics during the active phase of therapy in association with mechanical debridement (11). Indeed, early intake of antibiotics could result in rapid and significantly reduce in keystone pathogens leading to a greater recolonization of the periodontal pockets by beneficial species (27,28). Furthermore, the degree of periodontal tissue inflammation during the active phase of therapy, may provide a higher antibiotic concentration and uptake in subgingival space (24).

Concerning the clinical benefits of early antibiotic administration, it could reduce the need for subsequent non-surgical and surgical interventions because of a decreased number of residual pockets (29-33) which may represent an important benefit to patients in many terms. First, it may avoid the risk of hard tissue trauma from repeated attempts of instrumentation in locally

unresponsive sites or sites with recurrent disease (34). Second, it may also avoid the risks, stress and financial costs associated with surgical procedures. Furthermore, the immediate antibiotic usage at initial therapy provided beneficial clinical responses earlier in the treatment compared to its later usage at reevaluation phase. This rapid suppression of the periodontal infection could avoid the higher risk of future disease progression and of the potential systemic health consequences (11).

On the other hand, delaying antibiotic therapy to the second surgical treatment phase may be supported by the fact that scaling and root planing alone can be enough to control disease progression in most cases of periodontitis. Furthermore, given the limitations of non-surgical mechanical debridement and the limited effects of antibiotics on intact biofilm, a pocket access surgery may be required to completely eliminate the subgingival biofilm and calculus and therefore potentiate the effectiveness of systemic antibiotic at re-treatment (35,36).

However, even though these arguments seem to be biologically plausible, the literature data do not support them (2).

Otherwise, the major benefit for the delay in prescribing the antibiotics at the reevaluation phase relates to the avoidance of the risks associated with the administration of antibiotics, such as the development of side effects and the emergence of 'new' antibiotic-resistant species (11). Nonetheless, no major side effects are likely to be associated with the systemic administration of metronidazole and amoxicillin (26,29,31,37,38) and the potential risk of causing resistant strains against the antibiotics used in the periodontal therapy is a controversial issue in the current literature (39,40). It has been suggested that the increase in proportions of antibiotic resistant species in the subgingival biofilm seem to be rather the consequence of selection of organisms that were initially resistant to the antibiotic before antibiotic intake for periodontal purposes (41-43). Data assessing the emergence of 'new' antibiotic-resistant species are not available in the literature and conducting studies specifically designed to answer this question is very difficult (11).

Otherwise, according to Mombelli (36), the treatment of a periodontal infection, once in a punctual way, with two drugs with different antimicrobial action (Amoxicillin and Metronidazole), in a controlled situation following mechanical debridement, contributes probably little to the problem of resistance to antibiotics compared to the effects of the frequent prescription of antibiotics by dentists or doctors for other therapeutic and prophylactic purposes.

Therefore, in view of all these arguments, the recommendation to prescribe antibiotics in the active phase or at reevaluation in the treatment of periodontal infection should adhere to the same therapeutic principle used for the treatment of any other infection in the body, that is: the risks have to be broadly counterbalanced by expect-

ed benefits to the patient (11). In this regard, the possible negative effects of antibiotics including the potential risk of emergence of 'new' antibiotic-resistant species have to be balanced against the risk of delaying antibiotic prescription in terms of potential risk of systemic health consequences of a persisting periodontal infection, and the inconvenience, discomfort and financial consequences of further surgical or no-surgical retreatment (36).

Consequently, in our opinion, it may be judicious in the light of the new classification of periodontal diseases (44), to prescribe antibiotic as part of initial therapy in cases of periodontitis grade C, i.e. in cases where there is a risk of a rapid progression or a negative impact on systemic health and post-pone their prescription in the other cases of periodontitis at the reevaluation phase when mechanical debridement alone has not given successful results. However, our suggestion must be supported by more appropriate randomized clinical studies specifically designed for this purpose.

In conclusion, this systematic review didn't find a strong evidence to determine with certainty the ideal time for the adjunctive use of antibiotics. Some of included studies in this systematic review were of questionable quality of evidence. Furthermore, their heterogeneity makes comparison difficult and terminating conclusions even more. Despite this insufficient evidence, it seems that prescription of systemic antibiotic at the active phase of periodontal therapy leads to better clinical outcomes.

In future, more appropriate and standardized randomized clinical trials with longer follow-up periods must be conducted and completed by microbiological and immunological studies in order to evaluate the impact of timing of adjunctive antibiotic therapy on the outcome of periodontal therapy. Additional research into the pharmacokinetics of antibiotics in periodontal tissues during the different phases of periodontal therapy is also required to get a complete picture of the problem addressed.

References

- Haffajee AD, Socransky SS, Gunsolley JC. Systemic Anti-Infective Periodontal Therapy. A Systematic Review. *Ann Periodontol*. 2003;8:115-81.
- Herrera D, Alonso B, León R, Roldán S, Sanz M. Antimicrobial therapy in periodontitis: the use of systemic antimicrobials against the subgingival biofilm. *J Clin Periodontol*. 2008;35:45-66.
- Faggion CM, Cullinan MP, Atieh M, Wasiak J. An overview of systematic reviews of the use of systemic antimicrobials for the treatment of periodontitis. *Br Dent J*. 2014;217:443-51.
- Sgolastra F, Gatto R, Petrucci A, Monaco A. Effectiveness of systemic amoxicillin/metronidazole as adjunctive therapy to scaling and root planing in the treatment of chronic periodontitis: a systematic review and meta-analysis. *J Periodontol*. 2012;83:1257-69.
- Smiley CJ, Tracy SL, Abt E, Michalowicz BS, John MT, Gunsolley J, et al. Systematic review and meta-analysis on the nonsurgical treatment of chronic periodontitis by means of scaling and root planing with or without adjuncts. *J Am Dent Assoc*. 2015;146:508-524.e5.
- Jepsen K, Jepsen S. Antibiotics/antimicrobials: systemic and local administration in the therapy of mild to moderately advanced periodontitis. *Periodontol* 2000. 2016;71:82-112.

7. McGowan K, McGowan T, Ivanovski S. Optimal dose and duration of amoxicillin-plus-metronidazole as an adjunct to non-surgical periodontal therapy: A systematic review and meta-analysis of randomized, placebo-controlled trials. *J Clin Periodontol.* 2018;45:56-67.
8. Fritoli A, Gonçalves C, Faveri M, Figueiredo LC, Pérez-Chaparro PJ, Fermiano D, et al. The effect of systemic antibiotics administered during the active phase of non-surgical periodontal therapy or after the healing phase: a systematic review. *J Appl Oral Sci.* 2015;23:249-54.
9. Feres M. Antibiotics in the treatment of periodontal diseases: microbiological basis and clinical applications. *Ann R Australas Coll Dent Surg.* 2008;19:37-44.
10. Palmer RM, Watts TLP, Wilson RF. A double-blind trial of tetracycline in the management of early onset periodontitis. *J Clin Periodontol.* 1996;23:670-4.
11. Feres M, Figueiredo LC, Soares GMS, Faveri M. Systemic antibiotics in the treatment of periodontitis. *Periodontol 2000.* 2015;67:131-86.
12. Sanz M, Teughels W, Group A of European Workshop on Periodontology. Innovations in non-surgical periodontal therapy: Consensus Report of the Sixth European Workshop on Periodontology. *J Clin Periodontol.* 2008;35:3-7.
13. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *BMJ.* 2009;339:b2535.
14. Higgins JPT, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. *BMJ.* 2011;343:d5928.
15. Wells G, Shea B, O'Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 2014. Available from: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp
16. Mombelli A, Almaghouth A, Cionca N, Cancela J, Courvoisier DS, Giannopoulou C. Microbiologic response to periodontal therapy and multivariable prediction of clinical outcome. *J Periodontol.* 2017;88:1253-62.
17. Feres M, Retamal-Valdes B, Mestnik MJ, de Figueiredo LC, Faveri M, Duarte PM, et al. The ideal time of systemic metronidazole and amoxicillin administration in the treatment of severe periodontitis: study protocol for a randomized controlled trial. *Trials.* 2018;19:201.
18. Li Y, Xu L, Lu R, An Y, Wang X, Song W, et al. [Clinical effect of different sequences of debridement-antibiotic therapy in treatment of severe chronic periodontitis]. *Beijing Da Xue Xue Bao.* 2015;47:27-31.
19. Lu RF, Xu L, Feng XH, Meng HX. [Short term effect of combined use of amoxicillin and metronidazole at different time of non-surgical periodontal treatment for aggressive periodontitis]. *Zhonghua Kou Qiang Yi Xue Za Zhi.* 2012;47:666-70.
20. Giannopoulou C, Cionca N, Almaghouth A, Cancela J, Courvoisier DS, Mombelli A. Systemic Biomarkers in 2-Phase Antibiotic Periodontal Treatment: A Randomized Clinical Trial. *J Dent Res.* 2016;95:349-55.
21. Varela VM, Heller D, Silva-Senem MX, Torres MCMB, Colombo APV, Feres-Filho EJ. Systemic antimicrobials adjunctive to a repeated mechanical and antiseptic therapy for aggressive periodontitis: a 6-month randomized controlled trial. *J Periodontol.* 2011;82:1121-30.
22. Griffiths GS, Ayob R, Guerrero A, Nibali L, Suvan J, Moles DR, et al. Amoxicillin and metronidazole as an adjunctive treatment in generalized aggressive periodontitis at initial therapy or re-treatment: a randomized controlled clinical trial. *J Clin Periodontol.* 2011;38:43-9.
23. Mombelli A, Almaghouth A, Cionca N, Courvoisier DS, Giannopoulou C. Differential Benefits of Amoxicillin-Metronidazole in Different Phases of Periodontal Therapy in a Randomized Controlled Crossover Clinical Trial. *J Periodontol.* 2015;86:367-75.
24. Kaner D, Christan C, Dietrich T, Bernimoulin JP, Kleber BM, Friedmann A. Timing Affects the Clinical Outcome of Adjunctive Systemic Antibiotic Therapy for Generalized Aggressive Periodontitis. *J Periodontol.* 2007;78:1201-8.
25. Beliveau D, Magnusson I, Bidwell JA, Zapert EF, Aukhil I, Wallet SM, et al. Benefits of early systemic antibiotics in localized aggressive periodontitis: a retrospective study. *J Clin Periodontol.* 2012;39:1075-81.
26. Guerrero A, Griffiths GS, Nibali L, Suvan J, Moles DR, Laurell L, et al. Adjunctive benefits of systemic amoxicillin and metronidazole in non-surgical treatment of generalized aggressive periodontitis: a randomized placebo-controlled clinical trial. *J Clin Periodontol.* 2005;32:1096-107.
27. Socransky SS, Haffajee AD. Dental biofilms: difficult therapeutic targets. *Periodontol 2000.* 2002;28:12-55.
28. Teles RP, Haffajee AD, Socransky SS. Microbiological goals of periodontal therapy. *Periodontol 2000.* 2006;42:180-218.
29. Cionca N, Giannopoulou C, Ugolotti G, Mombelli A. Amoxicillin and metronidazole as an adjunct to full-mouth scaling and root planing of chronic periodontitis. *J Periodontol.* 2009;80:364-71.
30. Cionca N, Giannopoulou C, Ugolotti G, Mombelli A. Microbiologic testing and outcomes of full-mouth scaling and root planing with or without amoxicillin/metronidazole in chronic periodontitis. *J Periodontol.* 2010;81:15-23.
31. Feres M, Soares GMS, Mendes JAV, Silva MP, Faveri M, Teles R, et al. Metronidazole alone or with amoxicillin as adjuncts to non-surgical treatment of chronic periodontitis: a 1-year double-blinded, placebo-controlled, randomized clinical trial. *J Clin Periodontol.* 2012;39:1149-58.
32. Loesche WJ, Giordano JR, Hujoel P, Schwarcz J, Smith BA. Metronidazole in periodontitis: reduced need for surgery. *J Clin Periodontol.* 1992;19:103-12.
33. Loesche WJ, Giordano JR, Soehren S, Kaciroti N. The nonsurgical treatment of patients with periodontal disease: Results after five years. *J Am Dent Assoc* 2002;133:311-20. <https://doi.org/10.14219/jada.archive.2002.0170>
34. Mombelli A. Heresy? Treatment of chronic periodontitis with systemic antibiotics only. *J Clin Periodontol.* 2006;33:661-2.
35. Mombelli A. Antimicrobial advances in treating periodontal diseases. *Front Oral Biol.* 2012;15:133-48.
36. Mombelli A, Cionca N, Almaghouth A. Does adjunctive antimicrobial therapy reduce the perceived need for periodontal surgery? *Periodontol 2000.* 2011;55:205-16.
37. Silva MP, Feres M, Siroto TAO, Soares GMS, Mendes JAV, Faveri M, et al. Clinical and microbiological benefits of metronidazole alone or with amoxicillin as adjuncts in the treatment of chronic periodontitis: a randomized placebo-controlled clinical trial. *J Clin Periodontol.* 2011;38:828-37.
38. Mestnik MJ, Feres M, Figueiredo LC, Soares G, Teles RP, Fermiano D, et al. The effects of adjunctive metronidazole plus amoxicillin in the treatment of generalized aggressive periodontitis: a 1-year double-blinded, placebo-controlled, randomized clinical trial. *J Clin Periodontol.* 2012;39:955-61.
39. Veloo ACM, Seme K, Raangs E, Rurenga P, Singadji Z, Wekema-Mulder G, et al. Antibiotic susceptibility profiles of oral pathogens. *Int J Antimicrob Agents.* 2012;40:450-4.
40. Ardila CM, Granada MI, Guzmán IC. Antibiotic resistance of subgingival species in chronic periodontitis patients. *J Periodontol Res.* 2010;45:557-63.
41. Haffajee AD, Patel M, Socransky SS. Microbiological changes associated with four different periodontal therapies for the treatment of chronic periodontitis. *Oral Microbiol Immunol.* 2008;23:148-57.
42. Rodrigues RMJ, Gonçalves C, Souto R, Feres-Filho EJ, Uzeda M, Colombo APV. Antibiotic resistance profile of the subgingival microbiota following systemic or local tetracycline therapy. *J Clin Periodontol.* 2004;31:420-7.
43. Sedlacek MJ, Walker C. Antibiotic resistance in an in vitro subgingival biofilm model. *Oral Microbiol Immunol.* 2007;22:333-9.
44. Tonetti MS, Greenwell H, Kornman KS. Staging and grading of periodontitis: Framework and proposal of a new classification and case definition. *J Periodontol.* 2018;89:S159-72.

Conflict of interest

No potential conflict of interest relevant to this article was reported.